)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
Rapport Therapeutics
Rapport Therapeutics (RAPP) investor relations material
Rapport Therapeutics Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary5 Aug, 2026
Leadership and expertise
Executive team and board have extensive experience in neuroscience, biotech, and pharma, with backgrounds at major companies and successful track records in drug development.
Precision neuroscience platform and pipeline
Focus on small molecule precision medicines for neurological and psychiatric disorders, leveraging receptor associated proteins (RAPs) for high selectivity and specificity.
Lead program RAP-219 targets TARPγ8, a protein selectively expressed in brain regions implicated in focal onset seizures.
Pipeline includes programs for focal onset seizures, primary generalized tonic-clonic seizures, bipolar mania, chronic pain, migraine, and hearing/vestibular disorders.
RAP-219 clinical development and results
Phase 2a trial in drug-resistant focal onset seizures showed 71% median reduction in long episodes and 77.8% reduction in clinical seizures, with 24% achieving seizure freedom at 8 weeks.
RAP-219 was generally well tolerated, with most adverse events mild or moderate and a 10% discontinuation rate.
Phase 3 program initiated in Q2 2026, with two global, placebo-controlled trials underway.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Rapport Therapeutics
- Net loss widened to $76.5M despite $20M in new licensing revenue; cash runway extends into 2029.RAPP
Q2 2026 - RAP-219 delivers robust efficacy in drug-resistant epilepsy, advancing toward major market opportunities.RAPPCorporate presentation
- Phase 2A epilepsy data for RAP-219 expected Q3 2024, with pipeline and cash runway through 2026.RAPPTD Cowen 45th Annual Healthcare Conference
- Lead program demonstrates robust efficacy in epilepsy, with phase 3 trials and expansion planned.RAPPStifel 2025 Healthcare Conference
- RAP-219's pivotal epilepsy and bipolar trials advance with robust funding and global reach.RAPPStifel 2026 Virtual CNS Forum
- All director nominees and the audit firm were approved by stockholder vote.RAPPAGM 2026
- Global phase III epilepsy trials advance with robust data and broad commercial potential.RAPPGoldman Sachs 47th Annual Global Healthcare Conference 2026
- RAP-219 shows strong efficacy in epilepsy, with phase III and LAI programs advancing.RAPPJefferies Global Healthcare Conference 2026
- 77.8% median seizure reduction and 24% seizure freedom achieved, supporting Phase 3 trials.RAPPStudy Result
Next Rapport Therapeutics earnings date
Q3 20266 Nov, 2026
Rapport Therapeutics
Next Rapport Therapeutics earnings date
Q3 20266 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage